United States — United States Securities and Exchange Commission & MiNK Therapeutics

United States — United States Securities and Exchange Commission: The SEC is mentioned in connection with the whistleblower program, which may provide rewards for information. The SEC is not a direct party but is relevant to the regulatory context.

MiNK Therapeutics: MiNK Therapeutics is the defendant in the securities class action. The FDA clinical hold on ARD-101 and the alleged misrepresentations have caused a dramatic stock price decline and significant legal and financial exposure.

United States — United States Securities and Exchange Commission: The SEC is the regulatory body overseeing the offering through the shelf registration statement. Its role is regulatory and does not directly affect its market position.

MiNK Therapeutics: MiNK Therapeutics is the issuer of the offering, raising approximately $55 million to fund the U.S. commercial launch of LYTENAVA and for working capital. The offering provides necessary capital but may dilute existing shareholders.

United States — United States Securities and Exchange Commission: The SEC is mentioned in forward-looking statements as the regulator where Compass files reports.

MiNK Therapeutics: MiNK Therapeutics is the company whose abstract was accepted for an oral presentation at ESMO, a positive development for its pipeline.